Towards Improving the Efficacy of PSMA-Targeting Radionuclide Therapy for Late-Stage Prostate Cancer-Combination Strategies.

导出 OA

翻译打印收藏纠错

第一作者： Daria,Arbuznikova

第一单位： Department of Nuclear Medicine, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.

作者： Daria,Arbuznikova ^[1] ; Matthias,Eder ^[2] ; Anca-Ligia,Grosu ^[3] ; Philipp T,Meyer ^[4] ; Christian,Gratzke ^[5] ; Constantinos,Zamboglou ^[3] ; Ann-Christin,Eder ^[1]

作者单位： Department of Nuclear Medicine, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany. ^[1] Division of Radiopharmaceutical Development, German Cancer Consortium (DKTK), Partner Site Freiburg, Freiburg, Germany and German Cancer Research Center, Heidelberg, Germany. ^[2] Department of Radiation Oncology, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. ^[3] Department of Nuclear Medicine, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany. matthias.eder@uniklinik-freiburg.de. ^[4] Division of Radiopharmaceutical Development, German Cancer Consortium (DKTK), Partner Site Freiburg, Freiburg, Germany and German Cancer Research Center, Heidelberg, Germany. matthias.eder@uniklinik-freiburg.de. ^[5] Department of Urology, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. ^[6]

关键词 Combination therapy Lutetium-177-PSMA-617 Metastatic castration-resistant prostate cancer Prostate-specific membrane antigen Radioligand therapy